MedTech Dive March 1, 2024
Susan Kelly

BTIG analyst Marie Thibault said physicians could rapidly adopt the first-of-its-kind device.

Dive Brief:

  • Boston Scientific said Friday it has received Food and Drug Administration approval for a drug-coated balloon to treat coronary in-stent restenosis, a condition in which a vessel that previously received a stent narrows again due to plaque or scar tissue.
  • Approval for the device, which received FDA’s breakthrough designation in 2021, was supported by positive results from the prospective, randomized Agent trial that enrolled 600 patients at 40 U.S. sites, the company said.
  • “We view Agent highly favorably for its statistically significant superiority in what is a difficult-to-treat and common [in-stent restenosis] patient population, which we think could enable rapid physician adoption,” BTIG analyst Marie...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Medical Devices, Physician, Provider
Related Articles:
Medtronic, Tempus testing AI to find potential TAVR patients
AI Robot Scanner as Good as Rheumatologists at Assessing RA
Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices
From SpaceTech to MedTech: What medical device engineering teams can learn from aerospace
Boston Scientific to buy Intera Oncology, maker of liver cancer treatment

Share This Article